Drug Profile


Alternative Names: Ad5Ag85A; Recombinant genetic TB vaccine Ad5Ag85A; Recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A) - Tianjin CanSino Biotechnology; TB vaccine candidate - Tianjin CanSino Biotechnology/Aeras

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator McMaster University
  • Class Antituberculars; DNA vaccines; Gene therapies; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 13 Apr 2016 Phase I development is ongoing in Canada
  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
  • 08 Aug 2013 McMaster University terminates phase I trial in Tuberculosis (in volunteers, prevention) in Canada (NCT00800670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top